SCHEMBL5546084

SCHEMBL5546084

O=[C]OCCc1nnnn1-c1ccc(F)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 4/20 0.50
ALDH1A1 P00352 4/20 0.39
LMNA P02545 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MAPT P10636 3/20 0.39
PTGS2 P35354 4/20 0.39
PKM P14618 1/20 0.38
HTT P42858 1/20 0.38
NLRP3 Q96P20 1/20 0.38
TSHR P16473 1/20 0.37
KMT2A Q03164 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
JAK2 O60674 1/20 0.36
USP2 O75604 1/20 0.36
ALPL P05186 1/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
ALPG P10696 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5537170 0.86 ALDH1A1 (0.49) HSD11B1ALDH1A1LMNANPSR1L3MBTL1
SCHEMBL5543435 0.86 ALDH1A1 (0.48) HSD11B1ALDH1A1LMNANPSR1L3MBTL1
SCHEMBL5548018 0.86 HSD11B1 (0.53) HSD11B1ALDH1A1LMNANPSR1L3MBTL1
SCHEMBL5536565 0.84 HSD11B1 (0.44) HSD11B1ALDH1A1LMNANPSR1MAPT
SCHEMBL5544587 0.82 NPC1 (0.36) HSD11B1ALDH1A1L3MBTL1MAPTPKM
SCHEMBL5546087 0.81 HSD11B1 (0.50) HSD11B1ALDH1A1LMNANPSR1L3MBTL1
SCHEMBL5543968 0.77 POLB (0.48) HSD11B1ALDH1A1LMNAL3MBTL1MAPT
SCHEMBL9201834 0.77 HSD11B1 (0.54) HSD11B1ALDH1A1LMNANPSR1L3MBTL1
SCHEMBL5537088 0.76 ALDH1A1 (0.42) HSD11B1ALDH1A1LMNANPSR1MAPT
SCHEMBL9201843 0.74 HSD11B1 (0.54) HSD11B1ALDH1A1LMNANPSR1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
CN-101255170-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-09-03 CN disclosed
CN-101172981-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-05-07 CN disclosed
CN-100366624-C 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds OTSUKA PHARMA CO LTD (JP) 2008-02-06 CN disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 HSD11B1 256/4885ALDH1A1 355/4885LMNA 4152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.